Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes

المؤلفون المشاركون

Lee, Christine
Louie, Thomas J.
Weiss, Karl
Gerson, Marvin
Arnott, Wendy
Gorbach, Sherwood L.
Valiquette, L.

المصدر

Canadian Journal of Infectious Diseases and Medical Microbiology

العدد

المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-8، 8ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2016-05-24

دولة النشر

مصر

عدد الصفحات

8

التخصصات الرئيسية

الأحياء

الملخص EN

Background.

This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials.

Methods.

Patients received fidaxomicin or vancomycin 1.

Patients were assessed for clinical response recurrence of infection and sustained clinical response for 28 days after treatment completion.

Patients at increased risk of recurrence were subjected to subgroup analyses.

Results.

Clinical response rates for fidaxomicin (90.0%) were noninferior to those with vancomycin (92.2%; 95% confidence interval for difference: −7.7, 3.5).

However, fidaxomicin-treated patients had lower recurrence (14.4% versus 28.0%, p = 0.001 ) and higher sustained clinical response (77.1% versus 66.3%, p = 0.016 ).

Compared with vancomycin, fidaxomicin was associated with lower recurrence rates in all subgroups, reaching statistical significance in patients with age ≥ 65 years (16.0% versus 30.9%, p = 0.026 ), concomitant antibiotic use (16.2% versus 38.7%, p = 0.036 ), and non-BI strains (11.8% versus 28.3%, p = 0.004 ).

Higher sustained clinical response rates were observed for fidaxomicin compared with vancomycin in all subgroups; this was statistically significant in the non-BI subgroup (82.8% versus 69.1%, p = 0.021 ).

Conclusions.

In Canadian patients, fidaxomicin was superior to vancomycin in sustaining clinical response and reducing CDI recurrence.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Lee, Christine& Louie, Thomas J.& Weiss, Karl& Valiquette, L.& Gerson, Marvin& Arnott, Wendy…[et al.]. 2016. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology،Vol. 2016, no. 2016, pp.1-8.
https://search.emarefa.net/detail/BIM-1100012

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Lee, Christine…[et al.]. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology No. 2016 (2016), pp.1-8.
https://search.emarefa.net/detail/BIM-1100012

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Lee, Christine& Louie, Thomas J.& Weiss, Karl& Valiquette, L.& Gerson, Marvin& Arnott, Wendy…[et al.]. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology. 2016. Vol. 2016, no. 2016, pp.1-8.
https://search.emarefa.net/detail/BIM-1100012

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1100012